Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $1.4 million.

  • Aligos Therapeutics' Change in Accured Expenses fell 3323.8% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$659000.0, marking a year-over-year decrease of 13479.41%. This contributed to the annual value of -$1.4 million for FY2024, which is 25119.83% down from last year.
  • Aligos Therapeutics' Change in Accured Expenses amounted to $1.4 million in Q3 2025, which was down 3323.8% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Change in Accured Expenses ranged from a high of $6.1 million in Q2 2021 and a low of -$6.4 million during Q2 2022
  • Over the past 5 years, Aligos Therapeutics' median Change in Accured Expenses value was $897000.0 (recorded in 2022), while the average stood at -$95789.5.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 41227.32% in 2024, then soared by 632272.73% in 2025.
  • Over the past 5 years, Aligos Therapeutics' Change in Accured Expenses (Quarter) stood at $3.9 million in 2021, then plummeted by 38.47% to $2.4 million in 2022, then soared by 91.58% to $4.6 million in 2023, then crashed by 71.74% to $1.3 million in 2024, then grew by 8.28% to $1.4 million in 2025.
  • Its Change in Accured Expenses stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and -$4.8 million for Q1 2025.